Simmons Bank Has $2.74 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Simmons Bank grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 11.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 35,992 shares of the medical research company’s stock after buying an additional 3,653 shares during the period. Simmons Bank’s holdings in Edwards Lifesciences were worth $2,744,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in EW. Turtle Creek Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $34,000. Operose Advisors LLC boosted its holdings in Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 452 shares in the last quarter. SRS Capital Advisors Inc. grew its stake in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares during the period. NBC Securities Inc. bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $52,000. Finally, ORG Partners LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $66,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Edwards Lifesciences news, CEO Bernard J. Zovighian bought 580 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now owns 3,268 shares in the company, valued at $280,198.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $84.77, for a total value of $2,487,999.50. Following the completion of the transaction, the director now directly owns 4,486 shares of the company’s stock, valued at $380,278.22. The disclosure for this sale can be found here. Insiders sold a total of 237,749 shares of company stock valued at $20,920,934 over the last three months. Company insiders own 1.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EW. Oppenheimer raised their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. Wells Fargo & Company raised their target price on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. Citigroup raised their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Piper Sandler raised their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $93.27.

Edwards Lifesciences Trading Up 0.9 %

Shares of EW stock traded up $0.76 on Tuesday, reaching $85.85. 1,836,259 shares of the stock were exchanged, compared to its average volume of 3,735,495. The stock has a market cap of $51.73 billion, a PE ratio of 37.00, a P/E/G ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The stock has a 50 day moving average price of $90.05 and a 200 day moving average price of $79.69.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.